Mysler, Eduardo http://orcid.org/0000-0002-8993-0313
Azevedo, Valderilio Feijó http://orcid.org/0000-0002-2346-388X
Danese, Silvio http://orcid.org/0000-0001-7341-1351
Alvarez, Daniel
Iikuni, Noriko http://orcid.org/0000-0002-5541-9314
Ingram, Beverly
Mueller, Markus
Peyrin-Biroulet, Laurent http://orcid.org/0000-0003-2536-6618
Funding for this research was provided by:
Pfizer
Article History
Accepted: 14 September 2021
First Online: 27 October 2021
Declarations
:
: This work was funded by Pfizer.
: BI, DA, and MM are full-time employees of and own stock or options in Pfizer. NI was a full-time employee of Pfizer at the time the manuscript was developed and owns stock or options in Pfizer. EM received or has pending grants from Roche, Pfizer, Bristol-Myers Squibb and Novartis received honorarium from Eli Lilly, Pfizer, GlaxoSmithKline, Roche, Sanofi, AstraZeneca, Sandoz, Amgen, Gemmene, and AbbVie provided writing assistance, medicines, equipment, or administrative support to Pfizer, AbbVie, and Roche, and received payment for lectures including service on speakers’ bureaus to Eli Lilly, Pfizer, GlaxoSmithKline, Roche, Sanofi, AstraZeneca, Sandoz, Amgen, Gema Biotech, and AbbVie. VFA has received grants to conduct trials on biosimilars from Boehringer Ingelheim, consulting fees related to advisory boards from Pfizer, Amgen, and Sandoz, and payment for lectures provided to Pfizer, Amgen, Sandoz, Celltrion, and Janssen. SD reports consultancy fees from AbbVie, Allergan, Amgen, AstraZeneca, Athos Therapeutics, Biogen, Boehringer Ingleheim, Celgene, Celltrion, Eli Lilly, Enthera, Ferring Pharmaceuticals Inc., Gilead, Hospira, Inotrem, Janssen, Johnson & Johnson, MSD, Mundipharma, Mylan, Pfizer, Roche, Sandoz, Sublimity Therapeutics, Takeda, TiGenix, UCB Inc., and Vifor. LP-B served as a speaker, consultant, and advisory member for AbbVie, Allergan, Alma, Amgen, Applied Molecular Transport, Arena, Biogen, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Celltrion, Enterome, Enthera, Ferring, Fresenius Kabi SwissBioSim GmbH, Genentech, Gilead, Hikma, Index Pharmaceuticals, Janssen, Eli Lilly, MSD, Mylan, Nestle, Norgine, Oppilan Pharma, OSE Immunotherapeutics, Pfizer, Pharmacosmos, Roche, Samsung Bioepis, Sandoz, Sterna, Sublimity Therapeutics, Takeda, Tillots, and Vifor, received grants from AbbVie, MSD, and Takeda, and owns stock options from CTMA.
: This article does not contain any studies with human participants or animals performed by any of the authors.
: Not applicable.
: Not applicable.
: All authors participated in the structuring of this review, contributed to drafting and reviewing the work critically for important intellectual content, and approved the final submitted version.
: Not applicable.